Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma

Trachoma is caused by Chlamydia trachomatis and is a leading cause of blindness worldwide. Mass distribution of azithromycin (AZM) is part of the strategy for the global elimination of blinding trachoma by 2020. Although resistance to AZM in C. trachomatis has not been reported, there have been conc...

Full description

Bibliographic Details
Main Authors: Derek K-H. Ho, Christian Sawicki, Nicholas Grassly
Format: Article
Language:English
Published: Hindawi Limited 2015-01-01
Series:Journal of Tropical Medicine
Online Access:http://dx.doi.org/10.1155/2015/917370
id doaj-f19907bd56b34938900a7f072cd972cc
record_format Article
spelling doaj-f19907bd56b34938900a7f072cd972cc2020-11-24T23:54:04ZengHindawi LimitedJournal of Tropical Medicine1687-96861687-96942015-01-01201510.1155/2015/917370917370Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for TrachomaDerek K-H. Ho0Christian Sawicki1Nicholas Grassly2Department of Ophthalmology, William Harvey Hospital, Kennington Road, Willesborough, Ashford, Kent TN24 0LZ, UKDepartment of Anesthesia, University of Toronto, 123 Edward Street, Toronto, ON, M5G 1E2, CanadaSchool of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UKTrachoma is caused by Chlamydia trachomatis and is a leading cause of blindness worldwide. Mass distribution of azithromycin (AZM) is part of the strategy for the global elimination of blinding trachoma by 2020. Although resistance to AZM in C. trachomatis has not been reported, there have been concerns about resistance in other organisms when AZM is administered in community settings. We identified studies that measured pneumococcal prevalence and resistance to AZM following mass AZM provision reported up to 2013 in Medline and Web of Science databases. Potential sources of bias were assessed using the Cochrane Risk of Bias Tool. A total of 45 records were screened, of which 8 met the inclusion criteria. We identified two distinct trends of resistance prevalence, which are dependent on frequency of AZM provision and baseline prevalence of resistance. We also demonstrated strong correlation between the prevalence of resistance at baseline and at 2-3 months (r=0.759). Although resistance to AZM in C. trachomatis has not been reported, resistance to this commonly used macrolide antibiotic in other diseases could compromise treatment. This should be considered when planning long-term trachoma control strategies.http://dx.doi.org/10.1155/2015/917370
collection DOAJ
language English
format Article
sources DOAJ
author Derek K-H. Ho
Christian Sawicki
Nicholas Grassly
spellingShingle Derek K-H. Ho
Christian Sawicki
Nicholas Grassly
Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma
Journal of Tropical Medicine
author_facet Derek K-H. Ho
Christian Sawicki
Nicholas Grassly
author_sort Derek K-H. Ho
title Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma
title_short Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma
title_full Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma
title_fullStr Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma
title_full_unstemmed Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma
title_sort antibiotic resistance in streptococcus pneumoniae after azithromycin distribution for trachoma
publisher Hindawi Limited
series Journal of Tropical Medicine
issn 1687-9686
1687-9694
publishDate 2015-01-01
description Trachoma is caused by Chlamydia trachomatis and is a leading cause of blindness worldwide. Mass distribution of azithromycin (AZM) is part of the strategy for the global elimination of blinding trachoma by 2020. Although resistance to AZM in C. trachomatis has not been reported, there have been concerns about resistance in other organisms when AZM is administered in community settings. We identified studies that measured pneumococcal prevalence and resistance to AZM following mass AZM provision reported up to 2013 in Medline and Web of Science databases. Potential sources of bias were assessed using the Cochrane Risk of Bias Tool. A total of 45 records were screened, of which 8 met the inclusion criteria. We identified two distinct trends of resistance prevalence, which are dependent on frequency of AZM provision and baseline prevalence of resistance. We also demonstrated strong correlation between the prevalence of resistance at baseline and at 2-3 months (r=0.759). Although resistance to AZM in C. trachomatis has not been reported, resistance to this commonly used macrolide antibiotic in other diseases could compromise treatment. This should be considered when planning long-term trachoma control strategies.
url http://dx.doi.org/10.1155/2015/917370
work_keys_str_mv AT derekkhho antibioticresistanceinstreptococcuspneumoniaeafterazithromycindistributionfortrachoma
AT christiansawicki antibioticresistanceinstreptococcuspneumoniaeafterazithromycindistributionfortrachoma
AT nicholasgrassly antibioticresistanceinstreptococcuspneumoniaeafterazithromycindistributionfortrachoma
_version_ 1725467423481528320